Skip to main content
NCBI home page
Bentham Open Access logoLink to Bentham Open Access
. 2018 Jul;16(4):280–287. doi: 10.2174/1570162X17666181206111859

M918: A Novel Cell Penetrating Peptide for Effective Delivery of HIV-1 Nef and Hsp20-Nef Proteins into Eukaryotic Cell Lines

Bahareh Rostami 1, Shiva Irani 1, Azam Bolhassani 2,*, Reza Ahangari Cohan 3
PMCID: PMC6416460  PMID: 30520377

Abstract

Background:

HIV-1 Nef protein is a possible attractive target in the development of thera-peutic HIV vaccines including protein-based vaccines. The most important disadvantage of protein-based vaccines is their low immunogenicity which can be improved by heat shock proteins (Hsps) as an immunomodulator, and cell-penetrating peptides (CPPs) as a carrier.

Methods:

In this study, the HIV-1 Nef and Hsp20-Nef proteins were generated in E.coli expression system for delivery into the HEK-293T mammalian cell line using a novel cell-penetrating peptide, M918, in a non-covalent fashion. The size, zeta potential and morphology of the peptide/protein com-plexes were studied by scanning electron microscopy (SEM) and Zeta sizer. The efficiency of Nef and Hsp20-Nef transfection using M918 was evaluated by western blotting in HEK-293T cell line.

Results:

The SEM data confirmed the formation of discrete nanoparticles with a diameter of approxi-mately 200-250 nm and 50-80 nm for M918/Nef and M918/Hsp20-Nef, respectively. The dominant band of ~ 27 kDa and ~ 47 kDa was detected in the transfected cells with the Nef/ M918 and Hsp20-Nef/ M918 nanoparticles at a molar ratio of 1:20 using anti-HIV-1 Nef monoclonal antibody. These bands were not detected in the un-transfected and transfected cells with Nef or Hsp20-Nef protein alone indicating that M918 could increase the penetration of Nef and Hsp20-Nef proteins into the cells.

Conclusion:

These data suggest that M918 CPP can be used to enter HIV-1 Nef and Hsp20-Nef pro-teins inside mammalian cells efficiently as a promising approach in HIV-1 vaccine development.

Keywords: HIV, Cell-penetrating peptide, Heat shock protein 20, Nef, M918, Transfection

1. Introduction

Human immunodeficiency virus (HIV) is an important public health issue. In 2016, it was estimated that approximately 36.7 million people were living with a global HIV prevalence of 0.8% among adults [1]. The HIV genome includes three main genes encoding 15 viral proteins involved in the viral life cycle: a) env, gag and pol genes expressing proteins with the envelope, enzymatic and structural roles, respectively; b) tat and rev genes expressing the regulatory proteins; c) vpr, vip, vpu and nef expressing the accessory proteins [2, 3]. Among viral proteins, HIV-1 Nef is a protein with a molecular weight varying from 27 to 35 kDa which is expressed early in the viral life cycle. The Nef protein has major roles including inhibition of CD4 activity, stimulation of virus replication, and induction of apoptosis in both uninfected and infected cells [4]. Generally, the advantages of HIV-1 Nef as a good antigen candidate for HIV vaccine development include its expression in the first step of the infection, its presence during the period of viral infection, and possessing T-cell epitopes [5-10]. An effective vaccine should induce antibody response along with an increased cellular immunity against the viral infection. Among various vaccination strategies, the protein-based vaccines need to increase their potency due to poor immunogenicity [11]. Therefore, the researchers are investigating for the proper combination of antigens with effective adjuvants or carrier molecules in subunit vaccines such as protein-based vaccines. Heat shock proteins (HSPs) were suggested to increase immune responses against infectious diseases as an effective adjuvant [5, 12]. Among HSPs, there is a family of proteins with an average molecular weight of 20 kDa, known as Hsp20 that is mainly expressed in the brain and heart. It acts as a molecular chaperone which binds to protein kinase 1 (PDK1) and leads to its nuclear transport [12]. On the other hand, biological membranes are usually resistant to pass large and hydrophilic molecules which cause difficulties for their biomedical applications indicating the importance of improving their uptake into cells. Recently, several peptides with the ability to deliver polypeptides and oligonucleotides into the living cells have been now named as “cell-penetrating peptides” (CPPs) [13, 14]. CPPs are able to form the covalent or non-covalent complexes with different cargoes [15-18]. Generally, CPPs were determined as short (~30-35 amino acids residues), water-soluble and partly hydrophobic or polybasic peptides with a net positive charge at physiological pH. The main benefit of CPPs is that they are able to cross the cell membrane at low micromolar concentrations without causing significant membrane damage in vivo and in vitro [19-27]. Thus, it is of special importance to find novel and non-toxic CPPs with more extensive delivery properties. M918 peptide consists of 22 amino acids (MVTVLFRRLRIRRACGPPRVRV) derived from the C-terminal of the tumor suppressor protein p14ARF. This cationic CPP could be utilized for both covalent and non-covalent delivery of macromolecules in animal and plant cells [28]. For instance, M918 was efficiently transferred into HeLa and breast cancer cell lines, in a non-toxic approach up to concentrations of 25 µM [29]. Moreover, transduction of transposase sleeping beauty protein was reported using M918 [30]. In this study, we evaluated the potency of M918 peptide for antigen delivery in HEK-293T mammalian cell line. Herein, we utilized HIV-1 Nef accessory protein and Nef linked to Hsp20 as two antigenic models for HIV-1 vaccine development in the future.

2. Methods

2.1. Peptides

The M918 cell penetrating peptide (MVTVLFRRLRIRRACGPPRVRV), a highly hydrophobic and positively charged peptide, was synthesized by BioMatik Company (Canada).

2.2. Construction of the Recombinant Hsp20-Nef Plasmid

To construct the expression vector harboring HIV-1 Nef, the full length Nef gene (from HIV-1 vector pNL4-3, Accession No: AF324493.2, ~ 648) was previously cloned into the unique EcoRI/SalI cloning sites of the pET-23a [31]. Herein, for generation of pET-Hsp20-Nef, HIV-1 Nef sequence was digested from pET-Nef with EcoRI/SalI enzymes and ligated to the linearized pET23a-Hsp20 using T4 DNA ligase. It should be mentioned that for preparation of pET-Hsp20 construct, the full length of Mus musculus Hsp20 gene (Accession No: NM_001012401, ~ 581 bp) was previously subcloned from pQE-Hsp20 into the pET23a vector using NheI/HindIII restriction enzymes in our laboratory. The EcoRI/SalI restriction sites were designed after HindIII site in Hsp20 sequence. The recombinant pET-Hsp20-Nef was provided in a large scale using DNA extraction Mega Kit (Qiagen) and confirmed by digestion and sequencing.

2.3. Expression, Purification and Assessment of the Recombinant Protein

The process was performed according to our previous protocols [31]. Briefly, two E. coli BL21 and Rosetta strains were transformed with the recombinant pET-Hsp20-Nef plasmid. The transformants were selected on Luria-Bertani (LB) agar plate and grown to an optical density of 0.7-0.8 at 600 nm in Ty2x medium. The induction of protein expression with 1mM IPTG was optimized at different times of incubation (i.e., 2, 3, 4 and 16 h) and temperature scales (i.e., 25˚C and 37°C) after induction. The cell pellets were harvested and analyzed by 12% SDS-PAGE and western blotting using anti-Nef monoclonal antibody (Abcam). The recombinant Hsp20-Nef protein was purified by affinity chromatography using a Ni-NTA agarose column according to the manufacturer’s instructions (Qiagen). Further purification was performed by reverse staining method [32]. Next, the purified Hsp20-Nef protein was dialyzed against PBS1X, assessed by NanoDrop spectrophotometry, and stored at -70◦C until used. The endotoxin contamination was less than 0.5 EU/mg proteins as detected by LAL assay. It should be noted that the recombinant HIV-1 Nef protein could be successfully expressed, purified under denaturing conditions and dialyzed against PBS1X in our previous studies [31].

2.4. Physicochemical Characterization of the Non-covalent Peptide/ Protein Complexes

The M918/ Nef and M918/Hsp20-Nef complexes with molar ratios of 2:1, 5:1, 10:1, 15:1, 20:1 and 30:1 (1 µg Nef or Hsp20-Nef protein) were formed in a pyrogenic water and incubated for 30 min at room temperature. The formation of the complexes was confirmed by 12% SDS-PAGE electrophoresis. Their size and zeta potential were assessed by a Zetasizer Nano ZS instrument (Malvern Instruments, UK). In addition, their size and morphology were studied using a scanning electron microscope (SEM; KYKYEM3200 model, China).

2.5. Cell Culture

Human embryonic kidney cells (HEK-293T) were cultured in RPMI medium supplemented with 5% Fetal Bovine Serum (FBS, Gibco) at 37◦C in the presence of 5% CO2 atmosphere [5]. After several passages using trypsin-EDTA, the proliferated cells were counted and seeded into a 24-well plate for transfection and 96-well plate for cell viability assay.

2.6. Cell Viability Assay

For cell viability assay, HEK-293T cells (104 cells/ well) were seeded into 96-well microtiter plates in RPMI-1640 supplemented with 5% FBS and cultured for 16 h at 37°C in the presence of 5% CO2 atmosphere. After replacement of culture medium with fresh RPMI-1640, different concentrations of M918 peptide (2, 5, 10, 15, 20 and 30 µM), and various molar ratios of Hsp20-Nef/ M918 and Nef/ M918 complexes (2:1, 5:1, 10:1, 15:1, 20:1 and 30:1) were added to the cells and left for 48 h without exchanging the media. After 48 h of incubation, the media was removed and 20 μL of sterile filtered MTT stock solution (5 mg/ mL, sigma) in fresh RPMI-1640 media was added to each well. After 3 h, the media was removed and 100 μL dimethyl sulfoxide (DMSO) was added to each well to dissolve the formazan products. The color intensity (which is proportional to the number of viable cells) was assessed by an ELISA reader at

570 nm. The non-treated cells were used as a negative control (100% cell viability) as well as ethanol 70% as a positive control. MTT assay was performed in triplicate [33].

2.7. Transfection Assay of the Complexes into HEK-293T Cells

HEK-293T cells (6 × 104 cells/well) were seeded onto 24-well microtiter plates in complete RPMI-1640 medium (Sigma) supplemented with 5% FBS at 37◦C in an atmosphere containing 5% CO2. After growth of the HEK-293T cells to 80% confluency, the medium was replaced by serum-free medium and then 100 µl of each protein and complex (at a molar ratio of 20:1) was applied to each well. After 1 h incubation at 37◦C, the cells were supplemented with fresh RPMI, 5% FBS in a total volume of 200 µL medium without removal of the proteins and complexes overlay, and were further incubated for 3 h. Then, the cells were treated with trypsin-EDTA, harvested by centrifugation and resuspended in PBS 1X. The delivery of Nef and Hsp20-Nef proteins was confirmed by western blotting [33]. Briefly, for western blot analysis, protein bands were separated in 12% (w/v) polyacrylamide gel and transferred to nitrocellulose membrane (Millipore, USA). The anti-Nef-HRP monoclonal antibody (Abcam, 1:10000 v/v) was used to confirm the expression of Nef and Hsp20-Nef proteins under standard procedures. The immunoreactive protein bands were visualized using peroxidase substrate 3, 3’-diaminobenzidine (DAB, Sigma) [31].

2.8. Statistical Analysis

Statistical analysis (Student’s t-test) was performed by Prism 5.0 software (GraphPad, San Diego, California, USA) to analyze the percentage of cell viability (or cytotoxicity assay). The value of p < 0.05 was considered statistically significant. Similar results were obtained in two independent experiments.

3. Results

3.1. Generation of the Recombinant Hsp20-Nef Protein

The Hsp20-Nef gene was successfully cloned in pET23a expression vector. The presence of Hsp20-Nef gene was confirmed using digestion as a clear band of ~ 1230 bp migrated in agarose gel and also sequencing. The expression of Hsp20-Nef protein was analyzed in BL21 and Rosetta E.coli strains. The recombinant Hsp20-Nef protein could be expressed in Rosetta strain at 37◦C and 4 h post-induction. The data indicated that Hsp20-Nef could be successfully purified under denaturing conditions (Urea, pH= 4.5) and dialyzed against PBS1X. We used the reverse staining method after affinity chromatography due to the existence of additional bands in the purified protein and removing urea. The purified Hsp20-Nef protein migrated as a clear band of ~ 47 kDa in SDS-PAGE as indicated in Fig. (1A). Furthermore, the recombinant Hsp20-Nef protein was detectable using anti-Nef antibody in western blotting (Fig. 1B). The recombinant Hsp20-Nef protein had a concentration range between 0.6 and 0.8 mg/ml determined by NanoDrop spectrophotometry.

Fig. (1).

Fig. (1)

Open in a new tab

Expression and purification of Hsp20-Nef protein in E. coli expression system as shown in SDS-PAGE (A) and western blotting (B); A) Lane 1: Before induction, Lane 2: After induction, Lane 3: Purified protein using affinity chromatography, Lane 4-6: Further purification using reverse staining; B) Lane 1: Before induction, Lane 2: After induction, Lane 3: Purified protein; MW is the molecular weight marker (10-180 kDa, Fermentas).

3.2. Formation of M918/ Nef and M918/ Hsp20-Nef Complexes

The formation of M918/ Nef and M918/ Hsp20-Nef complexes was confirmed by SDS-PAGE analysis. As observed in Fig. (2), a chemical dissociation was detected as a dominant band of ~ 27 kDa and ~ 47 kDa related to Nef and Hsp20-Nef proteins, respectively, along with M918 peptide band in SDS-PAGE indicating the formation of complexes over a range of molar ratios of 1:2, 1:5, 1:10, 1:15, 1:20 and 1:30 (protein cargo: peptide carrier). Moreover, the size and morphology of nanoparticles were analyzed by SEM and Zeta sizer as shown in Fig. (3). These complexes formed the particles with an average diameter of 200-250 nm for M918/Nef and 50-80 nm for M918/Hsp20-Nef complexes at a molar ratio of 20:1. These data were in agreement with the particle hydrodynamic diameter and zeta potential analysis of M918/Nef (Surface charge/ Z-average: 13 mV; size: 464.9 nm) and M918/Hsp20-Nef (Surface charge/ Z-average: 17.87 mV; size: 294.2 nm) complexes at a molar ratio of 20:1 with dynamic light scattering. Moreover, the particle hydrodynamic diameter and zeta potential analysis of Nef protein, Hsp20-Nef protein and M918 peptide were approximately 359.1 nm & -8.55 mV, 241.9 nm & -9.15 mV, and 100 nm & 13.7 mV, respectively. The addition of M918 CPP to Nef or Hsp20-Nef proteins increased the diameter of the complexes in water. Their surface charges showed that Nef and Hsp20-Nef proteins exhibited negative charges (-8.55 and -9.15 mV), while their complexes displayed positive charges (13 mV and 17.87 mV). This suggests that the positive charges of M918 CPP/Nef or Hsp20-Nef complexes can be considered as an important factor for transport across the cell membrane of HEK-293T cells with the negative charges. Also, the Hsp20-Nef nanoparticles showed a significantly small size (50-80 nm) and positive charge as compared to the Nef nanoparticles (200-250 nm).

Fig. (2).

Fig. (2)

Open in a new tab

A) Analysis of M918/Nef (A) and M918/Hsp20-Nef (B) complexes at different molar ratios in SDS-PAGE: Lane 1) purified Nef or Hsp20-Nef protein as a control, Lane 2) M918 peptide, Lane 3) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 2:1, Lane 4) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 5:1, Lane 5) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 10:1, Lane 6) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 15:1, Lane 7) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 20:1, Lane 8) M918/ Nef or M918/Hsp20-Nef complexes at ratio of 30:1; MW is the molecular weight marker (10-180 kDa, Fermentas). The lanes 2-8 describe a chemical dissociation detected as a dominant band of ~ 27 kDa and ~ 47 kDa related to Nef and Hsp20-Nef proteins along with M918 peptide band in SDS-PAGE indicating the formation of protein/ peptide complexes.

Fig. (3).

Fig. (3)

Open in a new tab

The SEM micrograph of the spherical nanoparticles: A) M918 peptide, B) Hsp20-Nef, C) Hsp20-Nef/M918, D) Nef/M918, E) Nef; A size of ~ 200-250 nm was observed for M918/Nef nanoparticles and ~ 50-80 nm for M918/Hsp20-Nef nanoparticles at 25˚C.

3.3. In Vitro Cytotoxicity of M918 Peptide, M918/Nef and M918/Hsp20-Nef Complexes

According to the cell viability results, M918 peptide, M918/ Nef and M918/ Hsp20-Nef complexes at molar ratios of 2:1, 5:1, 10:1, 15:1, 20:1 and 30:1 did not represent any considerable cytotoxic effect compared to untreated cells over a period of 48 h (Fig. 4). Treatment of the cells with these compounds showed cell viability of 90-97% (p > 0.05). The cells treated with ethanol 70% significantly indicated a high decrease in viability (~10%) compared to other groups (p < 0.05).

Fig. (4).

Fig. (4)

Open in a new tab

Cell viability of the Nef, Hsp20-Nef, M918, M918/Nef and M918/Hsp20-Nef treatments: HEK-293T cells were treated with 1µg of the purified proteins, the complexes at different molar ratios of 2:1, 5:1, 10:1, 15:1, 20:1 and 30:1 (peptide: protein), M918 peptide (2, 5, 10, 15, 20 and 30 µM) as well as 70% ethanol as a positive control. The MTT assay was used to assess cytotoxicity. Data were presented as mean ± standard deviations from two independent experiments.

3.4. Cell Transfection Assay

The efficiency of Nef and Hsp20-Nef protein delivery was investigated in the HEK-293T cells transfected by the Nef/M918 and Hsp20-Nef/M918 nanoparticles at a molar ratio of 1: 20 as compared to the cells transfected by Nef and Hsp20-Nef protein, alone using western blotting. The dominant bands of ~27 kDa and ~47 kDa were detected in the transfected cells with M918/Nef and M918/Hsp20-Nef nanoparticles using the anti-HIV Nef monoclonal antibody at 3 h post-transfection. These bands were not revealed in the un-transfected cells (Fig. 5). Moreover, the transfected cells with Nef or Hsp20-Nef proteins alone did not detect any Nef/ Hsp20-Nef-related bands (data not shown) indicating that M918 could transfer Nef and Hsp20-Nef proteins into the cells.

Fig. (5).

Fig. (5)

Open in a new tab

Delivery efficiency of Nef and Hsp20-Nef proteins using M918 at a molar ratio of 1:20 (Nef/M918 and Hsp20-Nef/M918) in HEK-293 T cells for 3 h post-transfection: Western blot analysis showed delivery of the full-length Nef protein (~27 kDa, Lane 1) and Hsp20-Nef protein (~ 47 kDa, Lane 3) in transfected cells by M918 peptide at 3 h after transfection as compared to the un-transfected cells (Lane 2). The corresponding bands were not also detected in the transfected cells with Nef or Hsp20-Nef proteins alone similar to the un-transfected cells (data not shown). MW is the molecular weight marker (10-180 kDa, Fermentas).

4. Discussion

In the current study, we used a short cationic peptide carrier, M918, for delivery of the full-length HIV-1 Nef and Hsp20-Nef proteins into mammalian cells and evaluated its cytotoxicity and penetration efficiency in different doses. Our data indicated that the Nef or Hsp20-Nef/M918 complexes formed stable nanoparticles through the non-covalent binding with an average size of 200-250 nm and 50-80 nm, respectively. The potent delivery of HIV-1 Nef or Hsp20-Nef protein by M918 peptide at a molar ratio of 1: 20 (protein: peptide) was detected in HEK-293T cell line at 3 h post-transfection in a non-toxic approach.

Recent studies have been successful for clarification of some problems involved in the host immune response to HIV infections, but novel infections still continue to occur without an effective treatment [34]. Nef is one of the HIV proteins involved in the infection regulation [35]. Nuclear magnetic resonance (NMR) studies suggested that HIV-1 Nef was composed of a globular core region (aa 58-149, 181-206), a flexible N-terminal region (aa 1-57), and a C-terminal loop (aa 150-180) [36]. Nef protein could be considered as a possible attractive target in the development of therapeutic HIV vaccines such as protein-based vaccines. As known, the most important drawback of protein-based vaccines is their low immunogenicity [11]. New strategies have been developed to overcome this problem such as the use of adjuvants (e.g., Hsps) or carriers (e.g., CPPs). The studies showed that the identity and range of cargoes depend on the type and diversity of Hsp present within a vaccine [37]. Different Hsps are potent inducers of innate and adaptive immunity [38]. Among heat shock proteins, small HSPs are highly conserved proteins among all species which have a conservative α-crystallin domain (~90 amino acid residues) [39]. Alvarez et al. showed that the Leishmania Hsp20 as DNA vaccine elicited ~ 62% of the humoral responses against Hsp20 [40]. The reports demonstrated that Hsp20 was a highly conserved protein between species and has B and T lymphocyte epitopes [41, 42]. Moreover, Ortiz et al. reported that DNA fragment containing B and T cell epitopes of the N-terminal fragment of Hsp20 (NT-Hsp20) with other Babesia bovis antigens induced high levels of specific IgG antibodies [43]. Milani et al. reported the efficiency of a small Hsp (i.e., Hsp27) to increase Nef delivery in DNA vaccine [5]. Other finding showed that the use of Hsp27 in protein strategy could improve HIV-1 Nef-specific B- and T-cell immune [44]. Jafarzade et al. also indicated that HMGB1 DNA could be considered as a more efficient adjuvant for improvement of HIV Nef DNA-based immunization compared to Glycoprotein 96 (Gp96) DNA in vivo [45]. On the other hand, the therapeutic use of peptides and proteins was suppressed by the poor permeability of the plasma membrane which prevented the cellular uptake of large and hydrophilic molecules [33, 46]. Recently, a group of short, highly basic peptides known as cell penetrating peptides (CPPs) were used to carry and internalize efficiently the intact cargoes such as small molecules, plasmid DNA, small interfering RNA, proteins, viruses, and other various nanoparticles across the cellular membrane [33, 46]. These peptides were capable of internalizing non-covalently or covalently biological cargoes such as drugs with high efficiency and low toxicity [19]. Because CPPs provided a safe, effective and non-invasive method of transport for various cargos into cells, they were recently developed as vectors for the delivery of genetic and biologic products [47]. For instance, the amino acid 49-57 of HIV-1 Tat was able to transport therapeutic molecules into different cells [48, 49]. Several short amphipathic CPPs such as PEP and CADY families were also determined to deliver the therapeutic proteins or peptides through the formation of stable non-covalent complexes [50, 51]. In this line, the formation of Pep-1 and/ or Cady-2/ Nef protein complexes as discrete nanoparticles was confirmed by SEM analysis with an average size of ~150-250 nm [52]. Furthermore, the Pep-1 and Cady-2 delivery systems could increase the potency of Tat CPP conjugated to Nef (Tat-Nef) for cell penetration [52, 53]. Analysis of the immune responses demonstrated that the Tat-Nef + Gp96 DNA prime/Tat-Nef protein+Cady-2 boost regimen significantly enhanced the Nef-specific T cell responses [52]. On the other hand, a novel CPP, M918 could be used to translocate different cargoes inside various cells in a non-toxic fashion [29, 54]. M918 peptide contains seven arginine residues and was derived from the C-terminus of the tumor suppressor protein p14ARF. It was shown that secondary amphipathic cell penetrating peptides such as penetratin, pVEC, and M918 contain fewer amino acid residues as compared to the primary peptides [29, 55]. Holm et al. could increase the stability of M918 CPP as a potent transporter [56]. In addition, structural analyses of the peptide/lipid interactions indicated that peptides adopting a β-structure such as MPG and M918 were more sensitive to charges than the helical ones. In contrast, the interactions with the lipids involved both electrostatic and hydrophobic contributions for Pep-1 and Cady amphipathic peptides. Indeed, helical peptides showed a higher potential for peptide/lipids interactions than β-structured peptides [57-59]. Another study represented that FITC-labelled streptavidin was taken up by cells after formation of the non-covalent complexes with 5 μM M918. The authors were able to reduce this relatively high concentration to 1 μM and achieve much higher degrees of protein uptake without cell toxicity, when they biotinylated the peptide to improve streptavidin binding [29]. As similarly, in our study, no significant toxicity was detected in various doses of M918 peptide and different ratios of the nanoparticles (M918/Nef & M918/Hsp20-M918), thus this peptide may have a potential for in vivo studies.

Conclusion

Our main goal of this study was to clarify the transfection potency of M918 complexed with Nef or Hsp20-Nef proteins without covalent binding as compared to proteins alone. At first, the recombinant Hsp20-Nef protein was expressed in E.coli as His-tagged protein and purified by affinity chromatography using Ni-NTA column and then reverse staining. It was shown that M918 forms stable nanoparticles with the Nef or Hsp20-Nef proteins. The Hsp20-Nef/M918 nanoparticles had a more positive charge and smaller size as compared to Nef/M918 nanoparticles. Moreover, MTT assay showed that there is no toxicity for M918 and the nanoparticles at the selected doses on HEK-293T cell line in comparison with the untreated cells. In general, protein uptake into mammalian cells using M918 cell penetrating peptide through the formation of non-covalent complexes will be an effective approach for protein vaccination. However, further studies are required to determine its therapeutic efficiency in vivo.

Acknowledgements

Declared none.

Ethics Approval and Consent to Participate

Not applicable.

Human and Animal Rights

No Animals/Humans were used for studies that are the basis of this research.

Consent for Publication

Not applicable.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

References

  • 1.HIV/AIDS JUNPo . Global AIDS update. Geneva, Switzerland: 2016. [Google Scholar]
  • 2.Mann J.K., Ndungu T. HIV-1 vaccine immunogen design strategies. Virol. J. 2015;12(1):3. doi: 10.1186/s12985-014-0221-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kirchhoff F. HIV life cycle: overview. Encyclo AIDS; 2013. pp. 1–9. [Google Scholar]
  • 4.Geyer M., Fackler O.T., Peterlin B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2001;2(7):580–585. doi: 10.1093/embo-reports/kve141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Milani A., Bolhassani A., Heshmati M. Delivery of HIV-1 Nef linked to heat shock protein 27 using a cationic polymer is more effective than cationic lipid in mammalian cells. Bratisl. Lek Listy. 2017;118(6):334–338. doi: 10.4149/BLL_2017_064. [DOI] [PubMed] [Google Scholar]
  • 6.Gómez C.E., Nájera J.L., Jiménez V., et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. 2007;25(11):1969–1992. doi: 10.1016/j.vaccine.2006.11.051. [DOI] [PubMed] [Google Scholar]
  • 7.García F., Bernaldo de Quirós J.C., Gómez C.E., et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011;29(46):8309–8316. doi: 10.1016/j.vaccine.2011.08.098. [DOI] [PubMed] [Google Scholar]
  • 8.Safrit J.T., Fast P.E., Gieber L., Kuipers H., Dean H.J., Koff W.C. Status of vaccine research and development of vaccines for HIV-1. Vaccine. 2016;34(26):2921–2925. doi: 10.1016/j.vaccine.2016.02.074. [DOI] [PubMed] [Google Scholar]
  • 9.Perdiguero B., Gómez C.E., Cepeda V., et al. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. J. Virol. 2015;89:970–988. doi: 10.1128/JVI.02469-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hopkins K.L., Laher F., Otwombe K., et al. Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014;9(8):e103446. doi: 10.1371/journal.pone.0103446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lema D., Garcia A., De Sanctis J.B. HIV vaccines: a brief overview. Scand. J. Immunol. 2014;80(1):1–11. doi: 10.1111/sji.12184. [DOI] [PubMed] [Google Scholar]
  • 12.Basirnejad M., Bolhassani A., Sadat S.M. The distinct role of small heat shock protein 20 on HCV NS3 expression in HEK-293T cell line. Avicenna J. Med. Biotechnol. 2018;10(3):152–157. [PMC free article] [PubMed] [Google Scholar]
  • 13.Thorén P.E., Persson D., Karlsson M., Nordén B. The antennapedia peptide penetratin translocates across lipid bilayers–the first direct observation. FEBS Lett. 2000;482(3):265–268. doi: 10.1016/s0014-5793(00)02072-x. [DOI] [PubMed] [Google Scholar]
  • 14.Albrizio S., Giusti L., D’Errico G., et al. Driving forces in the delivery of penetratin conjugated G protein fragment. J. Med. Chem. 2007;50(7):1458–1464. doi: 10.1021/jm060935b. [DOI] [PubMed] [Google Scholar]
  • 15.Mussbach F., Franke M., Zoch A., Schaefer B., Reissmann S. Transduction of peptides and proteins into live cells by cell penetrating peptides. J. Cell. Biochem. 2011;112(12):3824–3833. doi: 10.1002/jcb.23313. [DOI] [PubMed] [Google Scholar]
  • 16.Kristensen M., Birch D., Mørck Nielsen H. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int. J. Mol. Sci. 2016;17(2):E185. doi: 10.3390/ijms17020185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Farkhani S.M., Valizadeh A., Karami H., Mohammadi S., Sohrabi N., Badrzadeh F. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78–94. doi: 10.1016/j.peptides.2014.04.015. [DOI] [PubMed] [Google Scholar]
  • 18.Vivès E., Schmidt J., Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochimica et Biophysica Acta (BBA). Rev. Can. 2008;1786(2):126–138. doi: 10.1016/j.bbcan.2008.03.001. [DOI] [PubMed] [Google Scholar]
  • 19.Madani F., Lindberg S., Langel Ü., Futaki S., Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011;2011:414729. doi: 10.1155/2011/414729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jiang Y., Li M., Zhang Z., Gong T., Sun X. Cell-penetrating peptides as delivery enhancers for vaccine. Curr. Pharm. Biotechnol. 2014;15(3):256–266. doi: 10.2174/1389201015666140813130114. [DOI] [PubMed] [Google Scholar]
  • 21.Bolhassani A., Jafarzade B.S., Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2017;87:50–63. doi: 10.1016/j.peptides.2016.11.011. [DOI] [PubMed] [Google Scholar]
  • 22.Tashima T. Intelligent substance delivery into cells using cell-penetrating peptides. Bioorg. Med. Chem. Lett. 2017;27(2):121–130. doi: 10.1016/j.bmcl.2016.11.083. [DOI] [PubMed] [Google Scholar]
  • 23.Hoffmann K., Milech N., Juraja S.M., et al. A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci. Rep. 2018;8:12538. doi: 10.1038/s41598-018-30790-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Säälik P., Elmquist A., Hansen M., et al. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug. Chem. 2004;15(6):1246–1253. doi: 10.1021/bc049938y. [DOI] [PubMed] [Google Scholar]
  • 25.Jafari S., Maleki Dizaj S., Adibkia K. Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. Bioimpacts. 2015;5(2):103–111. doi: 10.15171/bi.2015.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ngwa V.M., Axford D.S., Healey A.N., Nowak S.J., Chrestensen C.A., McMurry J.L. A versatile cell-penetrating peptide-adaptor system for efficient delivery of molecular cargos to subcellular destinations. PLoS One. 2017;12(5):e0178648. doi: 10.1371/journal.pone.0178648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Vasconcelos L., Pärn K., Langel U. Therapeutic potential of cell-penetrating peptides. Ther. Deliv. 2013;4(5):573–591. doi: 10.4155/tde.13.22. [DOI] [PubMed] [Google Scholar]
  • 28.Chugh A., Eudes F., Shim Y.S. Cell penetrating peptides: Nano-carrier for macromolecule delivery in living cells. IUBMB Life. 2010;62(3):183–193. doi: 10.1002/iub.297. [DOI] [PubMed] [Google Scholar]
  • 29.El-Andaloussi S., Johansson H.J., Holm T., Langel U. A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol. Ther. 2007;15:1820–1826. doi: 10.1038/sj.mt.6300255. [DOI] [PubMed] [Google Scholar]
  • 30.Jarver P., Fernaeus S., El-Andaloussi S., Tjornhammar M.L., Langel U. Co-transduction of sleeping beauty transposase and donor plasmid via a cell-penetrating peptide: a simple one step method. Int. J. Pept. Res. Ther. 2008;14:58–63. [Google Scholar]
  • 31.Milani A., Bolhassani A., Shahbazi S., Motevalli F., Sadat S.M., Soleymani S. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol. Lett. 2017;191:16–22. doi: 10.1016/j.imlet.2017.09.005. [DOI] [PubMed] [Google Scholar]
  • 32.Javanzad S., Bolhassani A., Doustdari F., Hashemi M., Movafagh A. Reverse staining method of polyacrylamide gels by imidazole-zinc salts for detection and purification of L1 capsid protein in E.coli. J. Paramed. Sci. 2013;4(2):33–37. [Google Scholar]
  • 33.Motevalli F., Bolhassani A., Hesami S., Shahbazi S. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo. Immunol. Lett. 2018;194:29–39. doi: 10.1016/j.imlet.2017.12.005. [DOI] [PubMed] [Google Scholar]
  • 34.Ajbani S. HIV vaccine development: current scenario and future prospects. J. AIDS Clin. Res. 2016;7(11):626. [Google Scholar]
  • 35.Lin L., Li H.S., Pauza C.D., Bukrinsky M., Richard Y.Z. Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res. 2005;15(11-12):923. doi: 10.1038/sj.cr.7290370. [DOI] [PubMed] [Google Scholar]
  • 36.Sugden S.M., Bego M.G., Pham T.N., Cohen E.A. Remodeling of the host cell plasma membrane by HIV-1 Nef and Vpu: A strategy to ensure viral fitness and persistence. Viruses. 2016;8(3):67. doi: 10.3390/v8030067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Segal B.H., Wang X-Y., Dennis C.G., et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today. 2006;11(11-12):534–540. doi: 10.1016/j.drudis.2006.04.016. [DOI] [PubMed] [Google Scholar]
  • 38.McNulty S., Colaco C.A., Blandford L.E., Bailey C.R., Baschieri S., Todryk S. Heat-shock proteins as dendritic cell-targeting vaccines-getting warmer. Immunology. 2013;139(4):407–415. doi: 10.1111/imm.12104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Fan G.C., Chu G., Kranias E.G. Hsp20 and its cardioprotection. Trends Cardiovasc. Med. 2005;15(4):138–141. doi: 10.1016/j.tcm.2005.05.004. [DOI] [PubMed] [Google Scholar]
  • 40.Montalvo-Alvarez A.M., Folgueira C., Carrion J., Monzote-Fidalgo L., Canavate C., Requena J.M. The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection. J. Biomed. Biotechnol. 2008:695432. doi: 10.1155/2008/695432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Brown W.C., Ruef B.J., Norimine J., et al. A novel 20-kilodalton protein conserved in Babesia bovis and B. bigemina stimulates memory CD4+ T lymphocyte responses in B.bovis-immune cattle. Mol. Biochem. Parasitol. 2001;118(1):97–109. doi: 10.1016/s0166-6851(01)00375-9. [DOI] [PubMed] [Google Scholar]
  • 42.Norimine J., Mosqueda J., Palmer G.H., Lewin H.A., Brown W.C. Conservation of babesia bovis small heat shock protein (Hsp20) among strains and definition of T helper cell epitopes recognized by cattle with diverse major histocompatibility complex class II haplotypes. Infect. Immun. 2004;72(2):1096–1106. doi: 10.1128/IAI.72.2.1096-1106.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ortiz J.M.J., Zajac M.P.D.M., Zanetti F.A., et al. Vaccine strategies against Babesia bovis based on prime-boost immunizations in mice with modified vaccinia Ankara vector and recombinant proteins. Vaccine. 2014;32(36):4625–4632. doi: 10.1016/j.vaccine.2014.06.075. [DOI] [PubMed] [Google Scholar]
  • 44.Milani A., Bolhassani A., Shahbazi S., Motevalli F., Sadat S.M., Soleymani S. Small heat shock protein 27: an effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity. Immunol. Lett. 2017;191:16–22. doi: 10.1016/j.imlet.2017.09.005. [DOI] [PubMed] [Google Scholar]
  • 45.Jafarzade B.S., Sadat S.M., Yaghobi R., Bolhassani A. Improving the potency of DNA vaccine encoding HIV-1 Nef antigen using two endogenous adjuvants in mouse model. Bratisl. Lek Listy. 2017;118(9):564–569. doi: 10.4149/BLL_2017_108. [DOI] [PubMed] [Google Scholar]
  • 46.Guo Z., Peng H., Kang J., Sun D. Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed. Rep. 2016;4(5):528–534. doi: 10.3892/br.2016.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Li H., Tsui T.Y., Ma W. Intracellular delivery of molecular cargo using cell-penetrating peptides and the combination strategies. Int. J. Mol. Sci. 2015;16(8):19518–19536. doi: 10.3390/ijms160819518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Cui Z., Patel J., Tuzova M., et al. Strong T cell type-1 immune responses to HIV-1 Tat (1–72) protein-coated nanoparticles. Vaccine. 2004;22:2631–2640. doi: 10.1016/j.vaccine.2003.12.013. [DOI] [PubMed] [Google Scholar]
  • 49.Torchilin V. Intracellular delivery of protein and peptide therapeutics. Drug Discov. Today. Technol. 2009;5:e95–e103. doi: 10.1016/j.ddtec.2009.01.002. [DOI] [PubMed] [Google Scholar]
  • 50.Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009;157:195–206. doi: 10.1111/j.1476-5381.2009.00057.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Munyendo W.L.L., Lv H., Benza-Ingoula H., Baraza L.D., Zhou L. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules. 2012;2:187–202. doi: 10.3390/biom2020187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kadkhodayan S., Jafarzade B.S., Sadat S.M., Motevalli F., Agi E., Bolhassani A. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model. Immunol. Lett. 2017;188:38–45. doi: 10.1016/j.imlet.2017.06.003. [DOI] [PubMed] [Google Scholar]
  • 53.Kadkhodayan S., Bolhassani A., Sadat S.M., Irani S., Fotouhi F. The efficiency of Tat cell penetrating peptide for intracellular uptake of HIV-1 Nef expressed in E. coli and mammalian cell. Curr. Drug Deliv. 2017;14(4):536–542. doi: 10.2174/1567201813666161006114448. [DOI] [PubMed] [Google Scholar]
  • 54.Sawant R.R., Patel N.R., Torchilin V.P. Therapeutic delivery using cell-penetrating peptides. Eur. J. Nanomed. 2013;5(3):141–158. [Google Scholar]
  • 55.Ruczynski E.J., Wierzbicki P.M., Kogut-Wierzbicka M., Mucha P., Siedlecka-Kroplewska K., Rekowski P. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells. Folia Histochem. Cytobiol. 2014;52(4):257–269. doi: 10.5603/FHC.a2014.0034. [DOI] [PubMed] [Google Scholar]
  • 56.Holm T., Räägel H., Andaloussi S.E.L., et al. Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochim. Biophys. Acta. 2011;1808:1544–1551. doi: 10.1016/j.bbamem.2010.10.019. [DOI] [PubMed] [Google Scholar]
  • 57.Eiríksdóttir E., Konate K., Langel U., Divita G., Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim. Biophys. Acta. 2010;1798:1119–1128. doi: 10.1016/j.bbamem.2010.03.005. [DOI] [PubMed] [Google Scholar]
  • 58.Deshayes S., Heitz A., Morris M.C., Charnet P., Divita G., Heitz F. Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry. 2004;43:1449–1457. doi: 10.1021/bi035682s. [DOI] [PubMed] [Google Scholar]
  • 59.Konate K., Crombez L., Deshayes S., et al. Insight into the cellular uptake mechanism of a secondary amphipathic cell penetrating peptide for siRNA delivery. Biochemistry. 2010;49(16):3393–3402. doi: 10.1021/bi901791x. [DOI] [PubMed] [Google Scholar]

Articles from Current HIV Research are provided here courtesy of Bentham Science Publishers

RESOURCES